20S proteasome Inhibitors
1 drugsAbout 20S proteasome
The 20S proteasome is a core component of the ubiquitin-proteasome system (UPS), responsible for degrading damaged or misfolded proteins to maintain cellular homeostasis. As a barrel-shaped structure, it plays a vital role in protein turnover within cells.
The 20S proteasome is an attractive drug target, particularly in oncology, due to its fundamental role in protein turnover. Currently, there is no genetic evidence directly linking the 20S proteasome to specific diseases.
One FDA-approved drug, KYPROLIS, targets the 20S proteasome for oncology indications. This drug is a small molecule developed by ONYX PHARMS AMGEN, demonstrating the clinical viability of targeting this protein degradation machinery.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 81% attractiveness score.
- White space opportunity in Relapsed Refractory Multiple Myeloma with only 2 trials.
- phase2 represents biological uncertainty with 53% completion.
Top 20S proteasome Drugs
ONYX PHARMS AMGEN is the only company with an approved drug targeting the 20S proteasome.
Low competition suggests high market entry barriers or limited perceived opportunity, requiring careful evaluation.
20S proteasome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 20S proteasome, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches like antibodies or PROTACs.
20S proteasome Clinical Trials 211 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 97 | 56 | 17 | 24 | 77% |
| Phase 2 | 82 | 28 | 15 | 37 | 65% |
| Phase 3 | 29 | 9 | 2 | 18 | 82% |
| Phase 4 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved 20S proteasome drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting 20S proteasome. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
20S proteasome Drug Approval Timeline (2012 - 2012)
KYPROLIS was first approved in 2012 and remains the only approved drug to date.
The lack of recent approvals indicates potential saturation or challenges in developing new 20S proteasome inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 140 clinical trials targeting 20S proteasome.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities